Chronic condition

Reliq Health Technologies, Inc. Announces Five New Contracts in AR, CA, NV and TX

Retrieved on: 
Friday, April 28, 2023

These new contracts are expected to add over 3,000 new patients to Reliq’s iUGO Care platform by the end of 2023, at an average revenue of $65 per patient per month.

Key Points: 
  • These new contracts are expected to add over 3,000 new patients to Reliq’s iUGO Care platform by the end of 2023, at an average revenue of $65 per patient per month.
  • Healthcare costs for chronic disease patients in Arkansas are expected to exceed $19 billion annually going forward unless the management of chronic disease in the state is improved.
  • All five clients will be using the iUGO Care Remote Patient Monitoring (RPM), Chronic Care Management (CCM) and Behavioural Health Integration (BHI) modules.
  • Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the Frankfurt Stock Exchange under the WKN:A2AJTB.

Global Metagenomic Market Analysis 2023 to 2027: by Applications, Technologies, Product and User - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 27, 2023

The "Metagenomic Markets: Global Market Analysis with Forecasts by Applications, Technologies, Product and User.

Key Points: 
  • The "Metagenomic Markets: Global Market Analysis with Forecasts by Applications, Technologies, Product and User.
  • 2023 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • This report looks at the technology, the applications, the users and the types of products that will be sold.
  • Understand growth expectations and the ultimate market forecasts for the next five years.

Pan-Biome Pharmaceuticals, a startup focused on age-related diseases and increasing human healthspan, reports positive results in a preclinical trial of colitis

Retrieved on: 
Tuesday, April 25, 2023

We have found that the compound demonstrates selective antimicrobial activity and has the ability to modulate the gut microbiome in mice.

Key Points: 
  • We have found that the compound demonstrates selective antimicrobial activity and has the ability to modulate the gut microbiome in mice.
  • Most age-related diseases are accompanied by chronic low-grade inflammation (Inflammaging), resulting in higher levels of pro-inflammatory cytokines in the bloodstream.
  • Pan-Biome’s lead compound activates anti-inflammatory cytokine IL-10 and inhibits the major pro-inflammatory cytokines TNF-a, IL-1b, and IL-6.
  • Pan-Biome CSO Dr. Poul Sorensen: “While we are still working out the mechanism, our compound most likely optimizes mitochondrial functionality.

The Physicians Foundation Launches Campaign to Help Physicians Address Patients' Drivers of Health

Retrieved on: 
Thursday, April 20, 2023

BOSTON, April 20, 2023 /PRNewswire/ -- The Physicians Foundation launched Let's Take 5 to Address Drivers of Health, a new campaign to support physicians in addressing their patients' drivers of health (DOH), such as food security and transportation access. The Physicians Foundation also announced the selection of five medical associations for a new grant program to support physicians to integrate DOH screening into their practices and build the capacity to improve patients' lives. These efforts expand on the Foundation's established leadership of recognizing and acting on the challenges of DOH for patients and physicians.

Key Points: 
  • BOSTON, April 20, 2023 /PRNewswire/ -- The Physicians Foundation launched Let's Take 5 to Address Drivers of Health , a new campaign to support physicians in addressing their patients' drivers of health (DOH), such as food security and transportation access.
  • The Physicians Foundation's 2022 Survey of America's Physicians brought to light the barriers that physicians face in addressing patients' DOH.
  • In fact, eight in 10 physicians believe that the U.S. cannot improve health outcomes or reduce health care costs without addressing DOH.
  • However, while nine in 10 physicians want to address drivers of health, six in 10 feel they have little to no time nor the ability to do so effectively.

Global Biosimilars Business and Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q1 2023 Update - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 18, 2023

The "Global Biosimilars Business and Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q1 2023 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Biosimilars Business and Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q1 2023 Update" report has been added to ResearchAndMarkets.com's offering.
  • In these volatile market conditions, the biosimilars market is still expanding dramatically, and the outlook is as promising.
  • It provides a detailed analysis of biosimilar market dynamics, covering clinical trials, patent data, financial deals, and company profiling details.
  • In addition, this report provides analyst commentary on key trends, drivers, strategies, innovations, and regulations in the field of biosimilars.

Biometrics Leader LifeQ Revolutionizes Healthcare with Disease Screening and Early Detection

Retrieved on: 
Monday, March 20, 2023

ATLANTA, March 20, 2023 /PRNewswire/ -- LifeQ, the company that uses globally-recognized watch brands to gather personalized, clinical-grade data, announced it can detect as many as 40 sleep and cardiovascular disorders with smart watches and other wearable devices, with an anticipated 100 diseases and disorders within the next two years—revolutionizing healthcare and improving consumers' lives. LifeQ co-founders Laurence (Laurie) Olivier, CEO, and Dr. Franco du Preez, Chief Science Officer, made the announcement.

Key Points: 
  • LifeQ co-founders Laurence (Laurie) Olivier, CEO, and Dr. Franco du Preez, Chief Science Officer, made the announcement.
  • LifeQ-enabled devices will help busy clinicians to detect important medical conditions, enable data-driven disease classification as well as facilitate disease prevention.
  • Screening for and flagging disease using wearables is possible through LifeQ's unique combination of photoplethysmography (PPG) and computational systems biology approach.
  • Wearable devices will soon enable insights for hundreds of diseases, providing a personalized action plan and a truly preventative approach to healthcare.

Modivcare Announces Appointment of Anne Bailey as President of its Home Division

Retrieved on: 
Monday, March 20, 2023

Modivcare Inc. (the “Company” or “Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving health outcomes, today announced the appointment of Anne Bailey as President of its Home division.

Key Points: 
  • Modivcare Inc. (the “Company” or “Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving health outcomes, today announced the appointment of Anne Bailey as President of its Home division.
  • “I am confident Anne is the right leader for our Home division as we expand our geographic footprint, enhance customer relationships, and drive innovative growth solutions,” said L. Heath Sampson, President and Chief Executive Officer of Modivcare.
  • Most recently, Anne was a senior executive and Group Vice President at DaVita, a Fortune 250 healthcare company.
  • Anne was also a founding member of DaVita’s Power of Women group and led DaVita’s community giving for many years.

United States Vital Signs Monitoring Devices Market Report 2023: Industry Outlook & Forecasts - An $11.21 Billion Market by 2028 from $7.21 Billion in 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 13, 2023

The "U.S. Vital Signs Monitoring Devices Market - Industry Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. Vital Signs Monitoring Devices Market - Industry Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. vital signs monitoring devices market is projected to be valued at $11.21 billion by 2028 from $7.21 billion in 2022, growing at a CAGR of 7.62% from 2022 to 2028.
  • COVID-19 pandemic has brought significant challenges to the entire healthcare industry and impacted the growth of the U.S. vital signs monitoring devices market.
  • Many U.S. vital signs monitoring devices market vendors are adopting various strategies to increase their presence in many major markets.

DarioHealth Reports Fourth Quarter and Record Revenue in Full-Year 2022 Financial and Operating Results

Retrieved on: 
Thursday, March 9, 2023

"Notably, operating loss in the fourth quarter declined by 58% to $9 million compared to $21.7 million in the fourth quarter of 2021 and non-GAAP operating loss in the fourth quarter declined by 60% to $6 million compared to $15 million in the fourth quarter of 2021.

Key Points: 
  • "Notably, operating loss in the fourth quarter declined by 58% to $9 million compared to $21.7 million in the fourth quarter of 2021 and non-GAAP operating loss in the fourth quarter declined by 60% to $6 million compared to $15 million in the fourth quarter of 2021.
  • Gross profit as a percentage of revenues increased to 40.1% in the fourth quarter of 2022, from 9.1% in the fourth quarter of 2021, and 27.3% in the third quarter of 2022.
  • Total operating expenses for the fourth quarter of 2022 were $11.7 million compared with $22.2 million for the fourth quarter of 2021 and $16.4 million for the third quarter of 2022, a decrease of $10.5 million, or 47%, compared to the fourth quarter of 2021, and a decrease of $4.6 million, or 28.3%, compared to the third quarter of 2022.
  • Total operating expenses excluding stock-based compensation, acquisition expenses and depreciation for the fourth quarter of 2022 were $10 million compared to $16.4 million for the fourth quarter of 2021, and $11.4 million for the third quarter of 2022.

Dawn Health partners with leading pharmaceutical company to transform chronic care

Retrieved on: 
Thursday, February 23, 2023

We see a big potential in effectively leveraging our shared capabilities, building on the Dawn Health SaMD platform to support patients suffering from a range of chronic diseases", says Daniel Daugaard, Founder & CEO at Dawn Health.

Key Points: 
  • We see a big potential in effectively leveraging our shared capabilities, building on the Dawn Health SaMD platform to support patients suffering from a range of chronic diseases", says Daniel Daugaard, Founder & CEO at Dawn Health.
  • Chronic diseases are the leading cause of mortality in Europe, representing 86% of all deaths, according to the Chronic Disease Alliance1.
  • Accordingly, the treatment and management of these chronic diseases are the leading drivers of current healthcare costs today.
  • However, chronic care is experiencing considerable challenges due to significant capacity constraints and limited insights into patient outcomes and often dispersed care of patients across various care teams.